Clinical Trial Detail

NCT ID NCT02536794
Title MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Northwestern University
Indications

Her2-receptor negative breast cancer

Therapies

Durvalumab + Tremelimumab

Age Groups: adult

Additional content available in CKB BOOST